drugset / Trial / NCT02442414

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

Timeline

Start
2015-04-07
Primary completion
2019-11-26
Completion
2019-11-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject KBP-5209 Unknown 20 mg Oral

Indications

No indication recorded.